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Supplementary Figure legends 
Supplementary Figure 1 mRNA expression levels of Gpnmb in OLETF rats and 
generation of Gpnmb transgenic (Tg) mice. a. Northern blot analyses in various tissues in 
obese OLETF rats (O) and lean LETO rats (L). b. Western blot analyses of mature 
adipocytes and stromal vascular fraction (SVF) in wild type (WT), Gpnmb Tg and Gpnmb-/- 
mice under high fat high sucrose (HFHS) chow. c. Schematic diagram showing structure of 
transgene consisting of aP2 promotor, β-globin intron, coding region of Gpnmb cDNA and 
hGH polyA tail. Primers, AP2, Gpnmb-Tg-AS, Gpnmb-sequence-S1 and GnnmbAS1 were 
used for the screening for the Gpnmb Tg mice. d. Gpnmb Tg mice #1, #12 and #13 
demonstrated 824 and 600 bp PCR products using primer sets indicated in panel c.  
 
Supplementary Figure 2 Body weight (BW), fat pad weight and glucose metabolism in 
Gpnmb-/- mice. a. Western blot analyses in epididymal fat of Gpnmb-/- and Gpnmb+/+ mice 
under high fat-high sucrose (HFHS) chow. b. Body weight of Gpnmb-/- and Gpnmb+/+ male 
C57BL/6JJcl mice fed with HFHS and standard (STD) chow. c. Fat pad weight of Gpnmb-/- 
and Gpnmb+/+ mice at 25 weeks of age. d. The size distribution and the average size of 
adipocytes in epididymal adipose tissues of Gpnmb-/- and Gpnmb+/+ mice under HFHS chow. 
e. Periodic acid-Schiff (PAS) staining of epididymal adipose tissues of Gpnmb-/- and 
Gpnmb+/+ mice under HFHS chow. f and g. Glucose and insulin tolerance test of Gpnmb-/- 
and Gpnmb+/+ mice under HFHS chow at 15 weeks of age. All data are presented as mean ± 
standard deviation (SD). n=8. 
 
Supplementary Figure 3 Serum lipid profile and evaluation of liver fibrosis in 
Gpnmb-/- and Gpnmb+/+ mice. a. Total cholesterol, triglyceride, and LDL cholesterol in 
sera of Gpnmb-/- and Gpnmb+/+ mice fed HFHS chow. b. Sirius red staining of liver tissues of 
Gpnmb-/- and Gpnmb+/+ mice fed HFHS chow. c. Liver fibrosis areas of Gpnmb-/- and 
Gpnmb+/+ mice fed HFHS chow. d. Liver hydroxyproline contents of Gpnmb-/- and Gpnmb+/+ 
mice fed HFHS chow. All data are presented as mean ± standard deviation (SD). n=5. 
**p<0.01 vs. Gpnmb+/+ mice. 
 
Supplementary Figure 4 Body weight (BW), fat pad weight and glucose metabolism in 
Gpnmb transgenic (Tg) mice. a. Western blot analyses in epididymal fat of Gpnmb Tg and 
wild type (WT) mice under HFHS chow. b. Body weight of Gpnmb Tg and WT male 
C57BL/6JJcl mice fed with HFHS and STD chow. c. Fat pad weight of Gpnmb Tg and WT 
mice at 25 weeks of age. d. The size distribution and the average size of adipocytes in 
epididymal adipose tissues of Gpnmb Tg and WT mice under HFHS chow. e. Periodic 
acid-Schiff (PAS) staining of epididymal adipose tissues of Gpnmb Tg and WT mice under 
HFHS chow. f and g. Glucose and insulin tolerance test of Gpnmb Tg and WT mice under 
HFHS chow at 15 weeks of age. All data are presented as mean ± standard deviation (SD). 
n=8. 
 
Supplementary Figure 5 Serum lipid profile and evaluation of liver fibrosis in Gpnmb 
Tg and WT mice. a. Total cholesterol, triglyceride, and LDL cholesterol of Gpnmb Tg and 
WT mice fed HFHS chow. b. Sirius red staining of liver tissues of Gpnmb Tg and WT mice 
fed HFHS chow. c. Liver fibrosis areas of Gpnmb Tg and WT mice fed HFHS chow. d. Liver 
hydroxyproline contents of Gpnmb Tg and WT mice fedHFHS chow. All data are presented 
as mean ± standard deviation (SD). n=8. **p<0.01 vs. WT mice. 
  
Supplementary Figure 6 Quantitative RT-PCR in liver tissues. a. mRNA expression of 
Sod1, Sod2, Cat, Gpx1, Cybb, and Ncf1 were not altered in Gpnmb-/- and Gpnmb+/+ mice 
fed with high fat high sucrose (HFHS) chow. b. mRNA expression of Sod1 and Cat, 
anti-oxidative stress genes, were significantly increased in Gpnmb Tg mice. c and d. The 
oxidative stress in the liver demonstrated by malondialdehyde (MDA) was ameliorated in 
Gpnmb Tg mice compared with wild type (WT) mice fed with HFHS chow. All data are 
presented as mean ± standard deviation (SD). n=8. *p<0.05, **p<0.01 vs. WT mice. 
 
Supplementary Figure 7 mRNA and protein expression of Gpnmb. a. Relative mRNA 
expression of Gpnmb in epididymal fat and liver in Gpnmb transgenic (Tg) and wild type 
(WT) mice. All data are presented as mean ± standard deviation (SD). n=5 b. Western blot 
of Gpnmb and calnexin in plasma membrane and cytosolic fractions in liver tissues of 
Gpnmb-/- and Gpnmb Tg mice.  
 
Supplementary Figure 8 mRNA expression of COL1A1, MMP3, ACTA1, cell 
morphology and oxidative stress in LI90 cells transfected with p3xFLAG-mGpnmb. a. 
Relative mRNA expression of COL1A1, MMP3, ACTA1 and mGpnmb in LI90 cells 
transfected with p3xFLAG-mGpnmb. b. Immunofluorescence staining using anti-FLAG 
antibody in LI90 cells transfected with p3xFLAG-mGpnmb. c. Dihydroethidium staining and 
fluorescence intensity in LI90 cells transfected with p3xFLAG-mGpnmb. All data are 
presented as mean ± standard deviation (SD). n=3. **p<0.01 vs. LI90 cells transfected with 
p3xFLAG-Vector. 
 
Supplementary Figure 9 Serum GPNMB levels in the patients with nonalcoholic fatty 
liver disease (NAFLD). a. Serum GPNMB levels and NAS score in the patients with NAFLD. 
They were classified into three groups according to the NAS score. b. Serum GPNMB levels 
and necroinflammatory grading in the patients with NAFLD. They were classified into three 
groups (grade 1-3) according to the degree of liver steatosis and inflammation. 
 
Supplementary Figure 10 Schematic drawing for the function of Gpnmb. Gpnmb 
ameliorates fat accumulation and fibrosis in the liver of diet-induced obesity mice by 
reducing the oxidative stress. Gpnmb in hepatic macrophages and stellate cells interacts 
with calnexin and the serum soluble GPNMB is elevated in the patients with non-alcoholic 
steatohepatitis. 
 
 
Supplementary Figure 11 Uncropped images for the blots shown in Figure 1b, 
Supplementary Figure 2a, Supplementary Figure 3a, and Figure 4a. 
 
Supplementary Figure12 Uncropped images for the blots shown in Figure 5. 
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